Abstract: The present invention provides a phosphonic acid compound and a prodrug thereof, and preparation methods for and uses of the phosphonic acid compound and the prodrug thereof. Specifically, the present invention provides a compound of formula (I) or formula (I-A), wherein the compound of formula (I-A) is a prodrug form of the compound of formula (I). Upon experimental verification, the phosphonic acid compound of the present invention has good ENPP1 kinase inhibition activity, and can be used as a therapeutic agent for ENPP1-related diseases, and the phosphonic acid compound has good metabolic stability in-vivo. In addition, the phosphonate or amide prodrug compound provided by the present invention has relatively high oral bioavailability, and can overcome the defect that a phosphonic acid original drug compound cannot be taken orally.

Abstract: The present invention relates to an SOS1 inhibitor with a pyrido-fused-six-membered ring structure, a preparation method therefor, and use thereof. The SOS1 inhibitor has the structural formula shown in formula (I) and an inhibitory activity on SOS1, and can be used to treat head and neck cancer, lung cancer, a mediastinal tumor, a gastrointestinal tumor, prostate cancer, testicular cancer, a gynecological tumor, breast cancer, renal and bladder cancer, an endocrine tumor, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, mesothelioma, skin cancer, a peripheral nerve tumor, a central nervous system tumor, lymphoma, leukemia, Noonan syndrome, cardio-facio-cutaneous syndrome, and hereditary gingival fibromatosis and a related syndrome thereof.

Abstract: The present disclosure belongs to the technical fields of computational medicine and clinical oncology, and specifically relates to a molecular subtyping method for gastric cancer (GC) based on metabolic genes, a construction method for a prognostic prediction model and applications. In the present disclosure, metabolic process alterations are overall assessed, and new metabolic transcription patterns based on 456 metabolic gene-related signatures are identified. Three different metabolic patterns are validated by unsupervised consensus clustering analysis and independent datasets, and molecular and clinical pathological features of these three metabolite clusters have different metabolic gene expressions, pathway enrichments, gene variations, and survival outcomes.

Abstract: The present disclosure involves a compound of formula (I) having ENPP1 inhibitory activity, a pharmaceutical composition thereof, and use thereof. The present disclosure particularly involves a compound of formula (I), as well as a pharmaceutical composition containing the compound and a method for preventing or treating diseases using the compound, particularly for diseases or disorders mediated by ENPP1 abnormal activity.

Abstract: The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

Abstract: Disclosed in the present invention are a compound having a BRD4 inhibitory activity, a preparation method therefor and the use thereof. The structure of the compound having the BRD4 inhibitory activity of the present invention is as shown in formula I, and the definition of each substituent is as described in the description and claims. The compound of the present invention has a high bromodomain protein inhibitory activity, in particular a BRD4-targeting inhibitory activity, and can be used for the treatment and/or prevention of related diseases mediated by bromodomain proteins.

Abstract: The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract: The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.

Abstract: The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.

Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

Abstract: The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.

Abstract: The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.